Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Amin, Reshma ^a   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; LEVOFLOXACIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CYSTIC FIBROSIS; DECISION MAKING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; LIFE EXPECTANCY; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; REVIEW; STENOTROPHOMONAS MALTOPHILIA INFECTION; SYSTEMATIC REVIEW; VALIDITY; COMPLICATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS; STENOTROPHOMONAS MALTOPHILIA;

CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84906832018     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009249.pub3     Document Type: Review

References (42)

1. Aaron SD, Vandemheen KL, Ferris W, Ferguson D, Tullis E, Haase D, et al.Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomized, double-blind, controlled clinical trial. Lancet 2005;366(9484):463-71.
2. Ballestero S, Vírseda I, Escobar H, Suárez L, Baquero F. Stenotrophomonas maltophilia in cystic fibrosis patients. European Journal of Clinical Microbiology and Infectious Diseases 1995;14(8):728-9.
3. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clinical Microbiology Reviews 2012;25(1):2-41.
4. Canadian CF Patient Data Registry Report (CDPR). Annual Data Report 2002.
5. Cystic Fibrosis Foundation Patient Registry. 2002 Annual Data Report to the Center Directors 2003.
6. Dalboge CS, Hansen CR, Pressler T, Høiby N, Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis 2011; Vol. 10, issue 5:318-25.
7. Deeks JJ, Altman JG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd Edition. London: BMJ Publisher Group, 2001.
8. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. Journal of Clinical Microbiology 1998;36(7):1953-8.
9. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews 1998;11(1):57-80.
10. Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. Statistical Methods in Medical Research 2001;10(5):325-38.
11. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
12. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
13. Gibson RL, Burns JL. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
14. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2002;166(3):356-61.
15. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004;59(11):955-9.
16. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;21(6):1754-60.
17. Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, et al.Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clinical Infectious Diseases 2002;35(3):228-35.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
19. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis. A center-based analysis. Chest 2003;123(1):20-7.
24. Kagen J, Zaoutis TE, McGowan KL, Luan X, Shah SS. Bloodstream infection caused by Stenotrophomonas maltophilia in children. Pediatric Infectious Disease Journal 2007;26(6):508-12.
25. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. European Respiratory Journal 2004;23(1):98-102.
26. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. Journal of Cystic Fibrosis 2009;8(6):386-91.
27. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al.Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clinical Infectious Diseases 1996;22(3):508-12.
28. Paez JI, Tengan FM, Barone AA, Levin AS, Costa SF. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. European Journal of Clinical Microbiology and Infectious Diseases 2008;27(10):901-6.
29. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
30. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
31. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al.Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine 1999;340(1):23-30.
32. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. Journal of Clinical Microbiology 2003;41(8):3548-58.
33. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al.Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 2001;139(3):359-65.
34. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2004;48(1):168-71.
35. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteraemia. Clinical Infectious Diseases 2002;34(12):1653-6.
36. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Barmeier H, et al.Prospective evaluation of emerging bacteria in cystic fibrosis. Journal of Cystic Fibrosis 2005;4(1):41-8.
37. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatric Pulmonology 2000;30(1):10-5.
38. Tsai WP, Chen CL, Ko WC, Pan SC. Stenotrophomonas maltophilia bacteraemia in burn patients. Burns 2006;32(2):155-8.
39. VanDevanter D, ORiordan M, Blumer J, Konstan M. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respiratory Research 2010;11(137):1-8.
40. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, et al.Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. American Journal of Respiratory and Critical Care Medicine 2011;183(5):635-40.
41. Waters V, Atenafu EG, Salazar JG, Lu A, Yau Y, Matukas L, et al.Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. Journal of Cystic Fibrosis 2012; Vol. 11, issue 1:8-13.
42. Amin R, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI:].